Compare Stocks → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CNATNASDAQ:EPIXNASDAQ:NRBONASDAQ:PHASNASDAQ:SVRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNATConatus Pharmaceuticals$0.35$1.00$0.23▼$1.07$11.61M1.841.28 million shs6,956 shsEPIXESSA Pharma$6.12-2.1%$8.32$2.56▼$11.67$270.75M1.62135,637 shs64,765 shsNRBONeuroBo Pharmaceuticals$3.06-1.3%$4.47$2.89▼$6.75$15.01M-0.251.05 million shs1,823 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shsN/ASVRASavara$4.45+5.0%$4.93$1.78▼$5.70$614.76M0.77852,109 shs1.25 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNATConatus Pharmaceuticals+0.03%-29.98%-10.23%+3.79%-63.16%EPIXESSA Pharma-2.34%-11.60%-30.86%-8.09%+133.21%NRBONeuroBo Pharmaceuticals+2.65%-10.40%-29.30%+2.65%-42.51%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%-76.19%SVRASavara-9.59%-14.52%-12.03%-14.86%+136.87%The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNATConatus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEPIXESSA Pharma1.6855 of 5 stars3.53.00.00.00.03.30.0NRBONeuroBo Pharmaceuticals0.9056 of 5 stars0.05.00.00.02.40.01.3PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara3.1122 of 5 stars3.55.00.00.02.61.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNATConatus PharmaceuticalsN/AN/AN/AN/AEPIXESSA Pharma3.00Buy$16.50169.61% UpsideNRBONeuroBo PharmaceuticalsN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/ASVRASavara3.00Buy$8.2084.27% UpsideCurrent Analyst RatingsLatest SVRA, EPIX, PHAS, CNAT, and NRBO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.003/4/2024SVRASavaraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $16.002/15/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNATConatus Pharmaceuticals$21.72M0.53N/AN/A$0.53 per share0.66EPIXESSA PharmaN/AN/AN/AN/A$3.30 per shareN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$3.44 per shareN/APHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00SVRASavaraN/AN/AN/AN/A$1.04 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNATConatus Pharmaceuticals-$11.39MN/AN/A∞N/A-52.42%-48.22%-39.32%N/AEPIXESSA Pharma-$26.58M-$0.59N/AN/AN/AN/A-17.41%-17.04%5/14/2024 (Estimated)NRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-59.42%-45.40%5/10/2024 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ASVRASavara-$54.70M-$0.33N/AN/AN/AN/A-46.27%-35.94%5/20/2024 (Estimated)Latest SVRA, EPIX, PHAS, CNAT, and NRBO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/A2/13/202412/31/2023EPIXESSA Pharma-$0.17-$0.14+$0.03-$0.14N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNATConatus PharmaceuticalsN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNATConatus PharmaceuticalsN/A16.2816.28EPIXESSA PharmaN/A40.7440.74NRBONeuroBo PharmaceuticalsN/A3.783.78PHASPhaseBio PharmaceuticalsN/A0.470.47SVRASavara0.1915.6615.66OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNATConatus Pharmaceuticals15.20%EPIXESSA Pharma75.12%NRBONeuroBo Pharmaceuticals1.37%PHASPhaseBio Pharmaceuticals49.02%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipCNATConatus Pharmaceuticals11.30%EPIXESSA Pharma14.70%NRBONeuroBo Pharmaceuticals0.79%PHASPhaseBio Pharmaceuticals9.90%SVRASavara4.58%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCNATConatus Pharmaceuticals3033.17 millionN/ANot OptionableEPIXESSA Pharma5044.24 million37.74 millionOptionableNRBONeuroBo Pharmaceuticals24.91 million4.87 millionNot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableSVRASavaraN/A138.15 million131.82 millionOptionableSVRA, EPIX, PHAS, CNAT, and NRBO HeadlinesSourceHeadlineSavara Inc. (SVRA) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com - April 25 at 8:08 PMSavara (NASDAQ:SVRA) Trading Down 6.6%marketbeat.com - April 24 at 6:51 PMSavara Inc (NASDAQ:SVRA) Shares Acquired by Jennison Associates LLCmarketbeat.com - April 24 at 7:27 AMJMP Securities Reiterates "Market Outperform" Rating for Savara (NASDAQ:SVRA)americanbankingnews.com - April 20 at 1:54 AMFYBR, BCRX and SABR are among after hour moversseekingalpha.com - April 20 at 1:53 AMSavara's (SVRA) Market Outperform Rating Reiterated at JMP Securitiesmarketbeat.com - April 18 at 2:21 PMSavara (NASDAQ:SVRA) Trading Down 3.9%marketbeat.com - April 17 at 12:20 PMSavara (NASDAQ:SVRA) Sees Large Volume Increasemarketbeat.com - April 15 at 1:54 PMVanguard Group Inc. Buys 789,249 Shares of Savara Inc (NASDAQ:SVRA)marketbeat.com - April 14 at 4:16 AMSavara Calls Out Haters!ghettoradio.co.ke - April 13 at 12:23 PMSavara (NASDAQ:SVRA) Shares Up 3.6%marketbeat.com - April 11 at 1:47 PMOptimistic Buy Rating for Savara Based on Molgramostim’s Market Potential and Study Outcomesmarkets.businessinsider.com - April 11 at 8:38 AMSavara (NASDAQ:SVRA) Trading Up 2.6%marketbeat.com - April 4 at 12:45 AMDetails of Savara’s Upcoming Projectsghettoradio.co.ke - March 27 at 5:19 AMSavara Announces New Employment Inducement Grantbusinesswire.com - March 22 at 4:05 PMSavara: Why Sauti Sol had to take a break from each othermpasho.co.ke - March 19 at 4:25 AMSavara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 Trialmsn.com - March 13 at 1:33 PMFDA lifts partial hold on Nurix Phase 1 study for NX-2127msn.com - March 11 at 6:57 PMBuy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with Molgramostimmarkets.businessinsider.com - March 11 at 1:57 PMSVRA Jul 2024 7.500 callfinance.yahoo.com - March 10 at 9:20 AMOptimistic Buy Rating for Savara on Molgramostim’s Market Potential and Strong Financialsmarkets.businessinsider.com - March 8 at 9:43 AMSVRA Stock Earnings: Savara Beats EPS for Q4 2023msn.com - March 7 at 11:08 PMSavara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Updatefinance.yahoo.com - March 7 at 6:08 PMBest penny stocks of March 2024usatoday.com - March 6 at 4:44 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksApril 25, 2024 2:14 AMView Stock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? Penny Stock Quantum-Si Incorporated Readies For Lift-OffApril 9, 2024 7:14 AMView Penny Stock Quantum-Si Incorporated Readies For Lift-OffAll Headlines Company DescriptionsConatus PharmaceuticalsNASDAQ:CNATConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.ESSA PharmaNASDAQ:EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.NeuroBo PharmaceuticalsNASDAQ:NRBONeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.